CTX320 Trademark

Trademark Overview


On Thursday, June 16, 2022, a trademark application was filed for CTX320 with the United States Patent and Trademark Office. The USPTO has given the CTX320 trademark a serial number of 97461218. The federal status of this trademark filing is SU - NON-FINAL ACTION - MAILED as of Thursday, June 12, 2025. This trademark is owned by CRISPR Therapeutics AG. The CTX320 trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Cells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy

Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy
ctx320

General Information


Serial Number97461218
Word MarkCTX320
Filing DateThursday, June 16, 2022
Status807 - SU - NON-FINAL ACTION - MAILED
Status DateThursday, June 12, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 23, 2024

Trademark Statements


Goods and ServicesCells for medical or clinical use in the field of in vivo gene editing therapy for the treatment of cardiovascular diseases; pharmaceutical and biopharmaceutical agents for the treatment of cardiovascular disease in the field of in vivo gene editing therapy; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cardiovascular disease in the field of in vivo gene editing therapy
Pseudo MarkCTX THREE TWO ZERO; CTX THREE HUNDRED TWENTY
Goods and ServicesGene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of in vivo gene editing therapy; gene editing, namely, pharmaceutical research and development in the field of in vivo gene editing therapy

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 30, 2022
Primary Code005
First Use Anywhere DateTuesday, March 5, 2024
First Use In Commerce DateTuesday, March 5, 2024

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, June 30, 2022
Primary Code042
First Use Anywhere DateTuesday, March 5, 2024
First Use In Commerce DateTuesday, March 5, 2024

Trademark Owner History


Party NameCRISPR Therapeutics AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressZUG V8 SWITZERLAND 6300
CH

Party NameCRISPR Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressZUG V8 SWITZERLAND 6300
CH

Trademark Events


Event DateEvent Description
Monday, June 20, 2022NEW APPLICATION ENTERED
Thursday, June 30, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 7, 2023ASSIGNED TO EXAMINER
Tuesday, February 14, 2023NON-FINAL ACTION WRITTEN
Tuesday, February 14, 2023NON-FINAL ACTION E-MAILED
Tuesday, February 14, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 11, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, May 11, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, July 3, 2023ASSIGNED TO EXAMINER
Thursday, August 10, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 10, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 11, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 2, 2023FINAL REFUSAL WRITTEN
Monday, October 2, 2023FINAL REFUSAL E-MAILED
Monday, October 2, 2023NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, December 18, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, December 18, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, February 27, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, February 27, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 27, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, March 16, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 18, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, October 28, 2024USE AMENDMENT FILED
Monday, October 28, 2024TEAS STATEMENT OF USE RECEIVED
Saturday, January 11, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 13, 2025STATEMENT OF USE PROCESSING COMPLETE
Tuesday, April 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, February 3, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 3, 2025NON-FINAL ACTION E-MAILED
Monday, February 3, 2025SU - NON-FINAL ACTION - WRITTEN
Wednesday, April 30, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, May 15, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 15, 2025ASSIGNED TO LIE
Thursday, May 15, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 12, 2025NON-FINAL ACTION E-MAILED
Thursday, June 12, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 12, 2025SU - NON-FINAL ACTION - WRITTEN